Conatus names executive VP, clinical development
This article was originally published in Scrip
Conatus Pharmaceuticals, a biotechnology company focused on the development and commercialization of medicines to treat liver disease, has named Dr David T Hagerty executive vice-president of clinical development. He will oversee the company's medical activities including clinical development, clinical operations, regulatory affairs, biostatistics, quality assurance and drug safety. Dr Hagerty has been an independent consultant in clinical development since April 2013. Prior to this he was senior vice-president and chief medical officer at Ardea Biosciences.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.